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ABSTRACT
The vascular environment can rapidly alter, and the speed with which
responses to both physiological and pathological changes are
required necessitates the existence of a highly responsive system.
The endothelium can quickly deliver bioactive molecules by regulated
exocytosis of its secretory granules, the Weibel−Palade bodies
(WPBs). WPBs include proteins that initiate both haemostasis and
inflammation, as well those that modulate blood pressure and
angiogenesis. WPB formation is driven by von Willebrand factor,
their most abundant protein, which controls both shape and size of
WPBs. WPB are generated in a range of sizes, with the largest
granules over ten times the size of the smallest. In this Cell Science at
a Glance and the accompanying poster, we discuss the emerging
mechanisms by whichWPB size is controlled and how this affects the
ability of this organelle to modulate haemostasis. We will also outline
the different modes of exocytosis and their polarity that are currently
being explored, and illustrate that these large secretory organelles
provide a model for how elements of secretory granule biogenesis
and exocytosis cooperate to support a complex and diverse set of
functions.
KEY WORDS: Endothelium, Organelle biogenesis, von Willebrand
factor
Introduction
The endothelial monolayer lining the vasculature acts as an active
interface between circulating blood and tissues. It must respond to
changes in both these environments to deal with damage that very
rapidly can have catastrophic consequences. To initiate a response
within a few seconds of vascular damage, the endothelium must be
able to deliver pre-made bioactive molecules by regulated
exocytosis. The endothelial secretory granule was first observed
by Ewald Weibel, when he worked in George Palade’s laboratory at
the Rockefeller institute in NewYork, on St Valentine’s day in 1962
(Weibel, 2012; Weibel and Palade, 1964). Although their function
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was then unknown, it was postulated that the purpose of these novel
long, cigar-shaped ‘cytoplasmic inclusions’ (later termed Weibel
−Palade bodies; WPBs) as seen by electron microscopy (EM) (see
poster), is associated with vascular or blood physiology. However,
the first functional cargo of WPBs was not identified until 1982
when the pro-haemostatic protein vonWillebrand factor (VWF) was
shown to localise within these organelles (Wagner et al., 1982). The
second WPB cargo to be identified was the leukocyte receptor
P-selectin (Bonfanti et al., 1989; McEver et al., 1989), which
demonstrated that WPBs are also involved in the inflammatory
response. New bioactive cargos of WPBs continue to be identified
and a current list of WPB cargos is summarised on the poster (albeit
the location of some cargos is complex; see, e.g. Knipe et al., 2010).
Another crucial advance was the discovery that these cytoplasmic
inclusions act as a store, thereby facilitating the regulated secretion
of VWF, when thrombin was shown to stimulate the release of VWF
from cultured endothelial cells (Levine et al., 1982). Subsequently,
both phorbol myristate acetate (PMA) and ionophores were found to
stimulate the release of VWF; this established what is still an
expanding list of agonists (Lowenstein et al., 2005) (see Table 1),
reflecting the range of physiological stimuli to which the
endothelium responds.
However, far from simply being an inert store for cargo, the active
interplay between VWF (during its biosynthesis) and its carrier
organelle (during its biogenesis) is being increasingly recognised.
Although the presence of VWF clearly drives the formation of
WPBs, the cellular machinery that controls the formation of this
organelle also influences the structural arrangement of VWF and,
thus, affects its functioning (Ferraro et al., 2014, 2016; Lui-Roberts
et al., 2005; Michaux et al., 2006; Wagner et al., 1991). This article
and the poster aim to show the essential features of WPB formation
and function, with a particular focus on the emerging role of
endothelial cells in actively controlling the amount and architecture
of VWF, which is released through their three different secretory
pathways (see below).
Biosynthesis ofVWF− thecargo that drives formationofWPB
VWF is a large multidomain molecule containing different binding
sites that mediate the crucial interactions needed to administer
vascular ‘first aid’. Some of these binding sites are only exposed
when the molecule is stretched under flow, and VWF is, thus, best
thought of as a mechanosensitive binding platform (Sadler, 2009;
Schneider et al., 2007; Springer, 2014). Following co-translational
translocation into the ER, VWF dimerises through its cysteine knot
domain located at its C-terminus, and is then trafficked to the Golgi
complex (see poster). Triggered by changes in the lumenal milieu of
the Golgi (acidic pH and Ca2+ ions), the dimers rearrange
themselves into so-called ‘dimeric bouquets’, in which their
central to carboxyl domains closely pair into a rod-like ‘stalk’,
with the amino-terminal D1-D3 domains forming a more-globular
shape to provide the ‘flower’ (Springer, 2014; Zhou et al., 2011)
(see poster). The trans-Golgi lumenal conditions also allow the
stacking of the dimers into a right-handed coil (Huang et al., 2008).
Here, the D1-D3 domains from juxtaposed dimers interact, thereby
forming the core of a tubule, with the stalks sticking out akin to a
bottlebrush. In this configuration, the dimers are correctly lined up
to allow for further disulphide-bond formation between D3 domains
that then generate multimers consisting of up to 50 dimers as
measured by multimer gel analysis. At the same time, still in the
Golgi lumen, the pro-peptide of VWF (encompassing D1-D2
domains) is proteolytically cleaved from the mature molecule by
furin (Wise et al., 1990). Cleaved mature and pro-peptide VWF
remain associated while they are kept within an environment of
acidic pH present in the Golgi and also later in WPBs. Importantly,
as a complete turn along the axis of a tubule accommodates on
average 4.2 dimers (with an axial mean length of 11 nm) and the
extended VWF dimer spans 120 nm (Fowler et al., 1985), tubulation
allows for an ∼45-fold compaction of VWF inside WPBs.
In a cell, there are different populations of WPB that vary in size
from ∼0.5−5 μm in their longest axis (i.e. length); these will be
packed with VWF tubules that can extend along the entire length of
the organelle. Because a single VWF multimer consisting of 50
dimers can only generate a 130-nm-long tubule, a tubule of 5 μm in
length must consist of many such multimers packed together by a
pH-sensitive mechanism (Sadler, 2009; Springer, 2014). The
tubules formed of coiled VWF inside WPBs can be seen by
conventional, cryo-EM and high-pressure freezing EM as bundles
of parallel electron-dense tubules surrounded by a limiting
membrane (Zenner et al., 2007) (see poster). Heterologous
expression of VWF can lead to formation of tubules that drive the
formation of pseudo-WPBs, which are indistinguishable from the
endothelial organelles as seen by EM (Wagner et al., 1991).
WPB size is controlled at the Golgi complex
While VWF biogenesis gives rise to VWF dimers that subsequently
assemble into tubules, another process runs in parallel (Ferraro et al.,
2014). During their transport from cis- to trans-Golgi mini-stacks
(the functional subunits of the Golgi, that are linked into a ribbon in
vertebrates), VWF dimers coalesce into a so-called ‘quantum’.
These quanta can be seen by super-resolution microscopy as peaks
of VWF immunoreactivity (see poster), or by transmission EM as a
periodic distribution of density (Ferraro et al., 2014). The size of the
quantum is determined by the dimensions of the Golgi mini-stack
(∼500−1000 nm in diameter) with the average quantum size
measured by super-resolution microscopy being around 500 nm. On
their final transfer to the trans-Golgi network (TGN), which
provides a continuous lumenal space, VWF quanta can be co-
packaged into nascent WPBs in a process that is dependent on the
Table 1. Endothelial cell agonists
Agonist Reference
ATP, ATP (Palmer et al., 1994)
Ca2+ ionophore (Loesberg et al., 1983)
Ceramide (Bhatia et al., 2004)
Complement components
(C5b, C6, C7, C8, C9)
(Foreman et al., 1994; Hattori et al., 1989)
Epinephrine (adrenaline) (Vischer and Wollheim, 1997)
Fibrin (Ribes et al., 1987)
Histamine (Hamilton and Sims, 1987)
Hydrogen peroxide* (Matsushita et al., 2005a)
Hypoxia (Pinsky et al., 1996)
IL-1, IL-6, IL-8, TNFα (Bernardo et al., 2004; Giddings and Shall,
1987; Paleolog et al., 1990)
Leukotrienes (Datta et al., 1995)
NO* (Matsushita et al., 2003)
Ox-LDL (Vora et al., 1997)
PMA (Giddings and Shall, 1987)
Radiation (Hallahan et al., 1998)
Reactive oxygen species (Vischer et al., 1995)
Serotonin (Palmer et al., 1994)
Shear stress (Galbusera et al., 1997)
Shiga toxin 1B and 2B (Nolasco et al., 2005)
Sphingosine-1 phosphate (Matsushita et al., 2004)
Thrombin (Levine et al., 1982)
Trauma (Reidy et al., 1989)
VEGF (Matsushita et al., 2005b)
*Inhibitor of WPB exocytosis.
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endocytic adaptor AP-1 and clathrin (Lui-Roberts et al., 2005). How
VWF tubules and their assembly at the TGN relate to the quanta is
not yet understood but, because tubules can be as long as an entire
WPB, they must be capable of extending beyond the size of a single
quantum.
The number of quanta that are co-packaged as a linear assembly
to form a WPB will control the ultimate size (i.e. length) of the
organelle. This results in a range of WPB sizes that show step-size
increases of ∼500 nm (the average size of a quantum). The balance
between short and long WPBs within a cell can be modulated.
siRNA-mediated ablation of Rab6a isoforms, which increases the
cisternal diameter of the mini-stacks in endothelial cells by
∼200 nm, gives rise to a corresponding increase in the size of the
VWF quanta and the resulting WPBs (Storrie et al. 2012; Ferraro
et al., 2014). Knockdown of the transcription factor KLF2 also
increases the size of WPBs by an as yet unknown cellular
mechanism (Ferraro et al., 2014, 2016). By contrast, unlinking of
the Golgi into mini-stacks − each one with their own small TGN −
by using genetic, physico-chemical or pharmacological approaches,
shifts the balance towards a production of shorter WPBs (or ‘mini-
WPBs’) (Ferraro et al., 2014, 2016). Alternatively, lowering the
expression level of VWF reduces the number of quanta being
delivered into the TGN; this decreases the probability of their co-
packaging, thereby also resulting in the predominant generation of
mini-WPBs (Ferraro et al., 2014) (see poster). The final size of
WPBs is set during their formation at the TGN, rather than by post-
Golgi homotypic fusion, as is the case for many granules (Hammel
et al., 2010). The size of WPBs has a major impact on VWF
function (Ferraro et al., 2014, 2016). By regulating the size of the
organelle, the cellular machinery is, thus, able to influence the acute
endothelial response.
Pathways of secretion−polarity and multimeric state
After formation and separation from the Golgi, WPBs move on
microtubules to the cell periphery where they anchor to actin fibres.
VWF multimerisation continues to occur within maturing WPBs
after they have left the TGN, together with compaction, which
results in organelles that appear opaque and thinner by EM
(Nightingale et al., 2009) (see poster). The multimerisation state of
VWF is of great physiological importance. For instance, the ability
of plasma VWF to recruit platelets disproportionately increases
with its multimeric state, and mutations in VWF that affect its
multimerisation cause the serious bleeding disorder von Willebrand
disease (Sadler, 2005). VWF multimerisation can be assayed by
using gel electrophoresis on SDS-agarose gels, where multimers
appear as a protein ladder on western blots (Ledford-Kraemer,
2010).
VWF is secreted via three pathways (Giblin et al., 2008).
Regulated and basal secretion both occur from WPBs and deliver
highly multimerised VWF. Regulated secretion is via an acute
pathway that is triggered by agonist-mediated activation of the
endothelium. In contrast, basal secretion occurs continuously. How
basal release is controlled is still largely unknown, but it probably
occurs in response to background levels of agonists and, possibly,
also to mechanical stimulation provided by circulating blood.
Finally, the third pathway occurs by constitutive release of VWF
and releases VWF that has not been sorted intoWPBs and, thus, has
not undergone high levels of multimerisation (Lopes da Silva and
Cutler, 2016) (see poster).
The release of VWF is also polarised, in that most of the highly
multimerised cargo that is delivered from WPBs through basal or
regulated secretion, is released from the apical surface of the
endothelium into the vessel lumen where it can engage with
platelets (Lopes da Silva and Cutler, 2016). However, constitutive
release of low-molecular-weight VWF occurs from the basolateral
surface of the endothelium, from which it incorporates into the
subendothelial matrix, and is likely to bind to collagen through its
A3 domain. The continuous basal release pathway is likely to be the
source of circulating plasma VWF, whereas the acute regulated
pathway provides a highly localised bolus of so-called ultra-large
(UL)-VWF in order to initiate primary haemostasis by recruiting
both plasma VWF and platelets.
Functional consequences of WPB size on VWF function
After its exocytosis, the agonist-stimulated secreted UL-VWF is
cleaved by the circulating protease ADAMTS13 into the less-
multimerised form that is found in plasma (Turner et al., 2012).
However, VWF that is released by regulated secretion first
transiently associates with the endothelial surface where it unfurls
under flow into long (up to millimetres in length) strings (Dong
et al., 2002). Since the largest observed VWF multimers (∼50
dimers, see above) can only extend for ∼6 μm, VWF strings must,
therefore, be formed by several multimers. These VWF strings are
highly efficient in recruiting not only platelets but also plasma VWF
(Ferraro et al., 2016). However, string formation is also dependent
on the initial coiling of VWF into tubules, as disruption of coiling
impairs an orderly unfurling and generates tangles of multimers that
fail to recruit platelets (Michaux et al., 2006).
Although the length of WPBs does not affect the size of VWF
multimers (Ferraro et al., 2016), it constrains the length of VWF
strings through a mechanism that is at present unclear. Shorter
WPBs produce shorter strings, and, as shorter strings have a reduced
capacity to recruit platelets and plasma VWF, these inevitably have
a reduced pro-haemostatic potential (Ferraro et al., 2014, 2016) (see
poster). WPBs are involved in the initial response to inflammation
(the rolling adhesion of leukocytes), as they carry the integral
membrane protein and leukocyte receptor P-selectin to the
endothelial surface to initiate the recruitment of leukocytes (Ley
et al., 2007). Leukocytes start adhering and rolling in proximity to
the inflamed site, until the adhesion becomes tight, and they finally
cross the endothelial monolayer andmigrate by chemoattraction into
the underlying inflamed tissue. Interestingly, WPB size does not
affect rolling adhesion of leukocytes (Ferraro et al., 2014, 2016).
However, secreted VWF has been shown to promote leukocyte
extravasation (Petri et al., 2010), yet the impact of WPB size on this
process has not been investigated. Modulation of WPB size, thus
has the potential to uncouple the haemostatic from the inflammatory
functions mediated by WPBs. This might solve the long-standing
question of how a single endothelial secretory granule can generate
different responses to inflammatory or haemostatic cues.
Modes and mechanisms of exocytosis
At steady state, WPBs are decorated with different Rab proteins and
anchored to actin stress fibres by the small GTPase Rab27A in
complex with the Rab effector MyRIP which, in turn, is bound to
myosin Va (Nightingale and Cutler, 2013; Nightingale et al., 2009;
Rojo Pulido et al., 2011) (see poster). Several other Rabs have been
localised to WPBs, including Rab3 (isoforms A, B and D), Rab15,
Rab33 and Rab37 (Knop et al., 2004; Zografou et al., 2012). Whilst
the functions of these Rab proteins are not entirely clear, both Rab3
and Rab15 have been shown to be important for VWF release from
stimulated cells (Bierings et al., 2012; Knop et al., 2004; Zografou
et al., 2012). Interestingly, some overlapping binding partners have
been identified, potentially offering clues as to the function of these
3613













Rab proteins. For example, both Rab27a and Rab15 bind Munc 13-
4 (also known as UNC13D) (Zografou et al., 2012), which is
required for agonist-stimulated release of VWF (Chehab et al.,
2017; Zografou et al., 2012). Furthermore, Rab27a and Rab3
(isoforms B and D) also share a binding partner in synaptotagmin-
like protein 4 (Slp4-a; also known as SYTL4) (Bierings et al., 2012).
Slp4-a is recruited to WPBs by Rab3 and acts as a positive regulator
of VWF release (Bierings et al., 2012). The balance between
Rab27a binding to its effectors MyRIP or Slp4-a can control
exocytosis. Binding of Rab27a to Slp4-a acts as a negative regulator
of the interaction between Rab27a and MyRIP, thereby disrupting
actin cytoskeleton anchoring and promotes exocytosis (Bierings
et al., 2012; Nightingale et al., 2009) (see poster).
Exactly how the process of WPBs docking to and fusing with the
plasma membrane proceeds is not fully understood. One relatively
well-characterised component is the small GTPase RalA (de Leeuw
et al., 2001, 1999; Rondaij et al., 2004) (see poster). Several
different agonists are able to bring about the release of the RalA
dissociation stimulator RalGDS from a complex it forms with β-
arrestin, allowing it to activate RalA at the plasma membrane
(Rondaij et al., 2008). Depletion of RalGDS inhibits the release of
VWF (Rondaij et al., 2008), whereas expression of constitutively
active RalA promotes release of WPBs (de Leeuw et al., 2001). One
way RalA might operate is through activation of phospholipase D1
(PLD1). PLD1 is required for VWF release (Disse et al., 2009;
Huang et al., 2012) and RalA can activate PLD1 in some cell types
(Vitale et al., 2005) − although this has not been demonstrated in
endothelial cells. Alternatively, in other cells types, RalA can
interact with components of the exocyst complex, which then
targets vesicles to the plasma membrane (Moskalenko et al., 2002).
Further details of the machinery involved in WPB exocytosis are
discussed in Box 1.
Unravelling the molecular mechanisms underlying WPB
exocytosis is complicated by the fact that endothelial cells can be
activated by such a range of agonists that, in turn, activate numerous
downstream signalling pathways (Table 1) (Rondaij et al., 2006). It
is generally considered that agonists work via two main pathways
that raise the intracellular levels of either Ca2+ or cyclic adenosine
monophosphate (cAMP) (Rondaij et al., 2006); examples are
thrombin − which acts via Ca2+, and epinephrine (also known as
adrenaline) − which signals through cAMP. However, this is a
simplified view. First, in vivo activation will most likely occur as a
result of stimulation by multiple agonists; epinephrine is always
present in plasma (Cryer, 1976). Similarly, many scenarios will
result in the generation or release of multiple endothelial agonists,
for example both thrombin and serotonin are likely to be
encountered by endothelial cells at sites of injury, as thrombin is
generated as part of the coagulation cascade and serotonin released
from activated platelets (Ivanciu and Stalker, 2015; Palmer et al.,
1994). However, very little is known about how stimulation with
combinations of different agonists influences WPB exocytosis.
Second, even when considering agonists that work through the same
pathway, the functional consequences that occur following
stimulation can be quite distinct. For example, both thrombin and
histamine act by raising Ca2+ levels, but result in distinct alterations
to the actin cytoskeleton (Vischer et al., 2000) and, consequently,
elicit different functional outcomes; thrombin promotes barrier
permeabilisation to a greater extent than histamine (Stolwijk et al.,
2016; Vischer et al., 2000). Different pathways and most likely
different machinery must, therefore, be activated following
stimulation with these agonists. Indeed, whilst agonists that raise
Ca2+ levels can promote the activation of protein kinase C (PKC)
isoforms (through Ca2+- or diacylglycerol-mediated activation) not
all of these agonists dependent on PKC to release VWF (Carew
et al., 1992; Lorenzi et al., 2008). By contrast, both histamine
(which signals through Ca2+) and forskolin (which signals through
cAMP) require the complex between annexin A2 and S100A10 for
the release of VWF (Brandherm et al., 2013; Knop et al., 2004).
Another interesting aspect of WPB exocytosis is that multiple
modes of exocytosis can be utilised, which can result in different
types and amounts of cargo being released. First, a ‘lingering kiss’ is
the endothelial slow-motion equivalent of the ‘kiss-and-run’ mode
that occurs during exocytosis of synaptic vesicles and
neuroendocrine granules; here, a partial fusion event leads to the
release of small molecules but not VWF (Babich et al., 2008).
Second, a full fusion of a single WPB with the plasma membrane
can also occur, with or without the formation of an actin−myosin
ring that helps to ‘squeeze out’ VWF cargo (Han et al., 2017;
Nightingale et al., 2009, 2011). Last, there are also circumstances
Box 1. Molecular machinery involved in WPB exocytosis
Fusion of WPBs with the plasma membrane is facilitated by soluble N-
ethylmaleimide-sensitive factor (NSF) attachment protein receptors
(SNAREs), residing on both WPB and the plasma membrane, both of
which interact to bring these membranes into close contact to trigger
fusion. A limited number of SNAREs and SNARE-binding proteins have
been found to play a role in WPB exocytosis. Two proteins of the vesicle-
associated membrane protein (VAMP) family − VAMP3 and VAMP8 –
were found localising to WPBs (Matsushita et al., 2003; Pulido et al.,
2011). However, only VAMP3 appears to have a function in WPB
exocytosis; incubation of human aortic endothelial cells with anti-VAMP3
antibodies or expression of dominant-negative VAMP3 in human
umbilical vein endothelial cells (HUVECs) significantly inhibits VWF
release (Matsushita et al., 2003; Pulido et al., 2011). Both VAMP3 and
VAMP8 can form a complex with two plasma membrane SNAREs,
syntaxin-4 and SNAP23 (Pulido et al., 2011; Zhu et al., 2014). These
SNAREs both appear to be necessary for WPB exocytosis. Depletion of
SNAP23 causes a significant fall in the stimulated release of VWF from
HUVECs and human dermal microvascular endothelial cells (HDMVEC)
(Han et al., 2017); although previous experiments in depleting SNAP23
failed to show any effect on VWF release in response to histamine,
potentially due to less-effective depletion of protein (Pulido et al., 2011).
Depletion of syntaxin-4 reduces the amount of P-selectin present on the
plasma membrane and also perturbs neutrophil adhesion, indicating an
inhibition of WPB exocytosis (Fu et al., 2005). The assembly of this
complex can be regulated to control WPB exocytosis: Munc18c (also
known as STXBP3) binds syntaxin-4, thus preventing its association with
SNAP23 and VAMP3 (Fu et al., 2005). Disruption of the interaction
between Munc18 and syntaxin-4 occurs following thrombin activation,
which leads to PKC-dependent phosphorylation of both proteins and
WPB exocytosis, evidenced by an increase in P-selectin levels on the
plasma membrane (Fu et al., 2005). This interaction might, in part, be
regulated through the activities of protein phosphatase 2B, which
interacts with Munc18c and is itself a positive regulator of VWF release
(Nolasco et al., 2009).
Syntaxin-binding proteins that might regulate WPB exocytosis have also
been identified. Syntaxin-binding protein 5 (STXBP5) binds syntaxin-4,
but not SNAP23, and is expressed in several endothelial cell typeswhere
it acts as a negative regulator of WPB exocytosis (Zhu et al., 2014).
Depletion of STXBP5 increases stimulated secretion of VWF in
endothelial cells, and STXBP5 knock-out mice display increased
levels of VWF in plasma (Zhu et al., 2014). By contrast, STXBP1
appears to be a positive regulator of WPB exocytosis; depletion of this
protein reduces stimulated secretion in HUVECs, and cells grown from
individuals carrying mutations in this gene are also defective in agonist-
induced secretion (van Breevoort et al., 2014). STXBP1 interacts with
the syntaxin-1 and -2 − but not with syntaxin-4 − as well as with the
Rab27a effector Slp4-a (see main text).
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where multiple WPBs can be present at a single fusion site (Kiskin
et al., 2014; Stevenson et al., 2017; Valentijn et al., 2010). Such
cumulative exocytic events occur whenWPBs fuse with a pre-fused
WPB, rather than with the plasma membrane directly. It is unclear
how these different modes of exocytosis influence different WPB
cargo and the ultimate functional response. However, VWF, with its
large multimers and complex quaternary structure is probably the
cargo that is most affected by the specific mechanism of exocytosis,
rather than smaller WPB cargos, such as cytokines. This is the case
for cumulative exocytosis; promotion of cumulative exocytosis (by
blocking compensatory endocytosis) impairs the release of VWF
and, consequently, the formation of VWF strings (Stevenson et al.,
2017). An exception is the lingering kiss, which only permits the
secretion of molecules less than ∼40 kDa. With regard to WPB
membrane cargos, the membrane protein CD63 can transfer to the
plasma membrane, but this mode of exocytosis also precludes the
transfer of P-selectin (Babich et al., 2008). Taken together, it is thus
likely that the different modes of exocytosis employed primarily
modulate the extent of the haemostatic function of WPBs. A key
challenge will be in identifying machinery that is specific for the
different modes of exocytosis. Whilst the focal adhesion proteins
Zyxin and α-actinin have recently been identified on the actin
−myosin ring (Han et al., 2017), very little is known about other
proteins that are involved in any of these exocytic modes.
Perspectives
WPBs, the secretory granules of endothelial cells, store bioactive
molecules that act as first-response mediators to re-establish
vasculature homeostasis. Although the function of WPBs in
haemostasis and inflammation is firmly established and the roles of
some of its cargos, particularly VWF, have been extensively studied,
there are many aspects that are not yet fully understood. First, to date
we do not have a definitive and complete list of WPB cargoes,
mainly owing to technical hindrances that include the fragility of
these organelles − making their purification difficult − and the
predominance of VWF as a WPB cargo, hindering the detection of
less-abundant cargos. Second, even though we have identified some
of the machinery involved in exocytosis, we still have very little idea
how it operates in concert, nor dowe have outlines of all the signalling
pathways that are involved in its regulation. Third, the emerging
plasticity of WPBs, especially with regard to how it is linked to the
control of their size, awaits further exploration − especially in vivo.
Last, the combined effects of all the factors noted above on WPB
physiology need to be established. Given their role in thrombosis and
inflammation alone, learning how to control WPB functioning will,
inevitably, have important consequences for clinical interventions.
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